Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
690
Views
21
CrossRef citations to date
0
Altmetric
Author's View

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

Alexandr V Bazhin Department of General Surgery; University of Heidelberg; Heidelberg, GermanyCorrespondence[email protected]
,
Jagadeesh Bayry INSERM Unité 872; Centre de Recherche des Cordeliers; Paris, France
,
Viktor Umansky Skin Cancer Unit; German Cancer Research Center (DKFZ); Heidelberg and Department of Dermatology; Venereology and Allergology; University Medical Center Mannheim; Ruprecht-Karl University of Heidelberg; Mannheim, Germany
,
Jens Werner Department of General Surgery; University of Heidelberg; Heidelberg, Germany
&
Svetlana Karakhanova Department of General Surgery; University of Heidelberg; Heidelberg, Germany
Article: e25736 | Received 10 Jul 2013, Accepted 11 Jul 2013, Published online: 23 Jul 2013

Figures & data

Figure 1. Double immunological consequences of pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) cells expressing tumor-associated antigens (A) activate the immune system in PDAC patients (B). This generally results in the elicitation of PDAC-specific immune responses (C). In addition, PDAC cells can activate the immunosuppressive arm of the immune system (D), thus damping antitumor immune responses (E).

Figure 1. Double immunological consequences of pancreatic ductal adenocarcinoma. Pancreatic ductal adenocarcinoma (PDAC) cells expressing tumor-associated antigens (A) activate the immune system in PDAC patients (B). This generally results in the elicitation of PDAC-specific immune responses (C). In addition, PDAC cells can activate the immunosuppressive arm of the immune system (D), thus damping antitumor immune responses (E).

Related Research Data

T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors.
Source: Wiley
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition
Source: bioRxiv

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.